A5101879696- Cancer Immunotherapy and Biomarkers
- Retinal Diseases and Treatments
- Retinal and Macular Surgery
- Neonatal and fetal brain pathology
- Retinopathy of Prematurity Studies
- Adenosine and Purinergic Signaling
- Retinal and Optic Conditions
- Neonatal Respiratory Health Research
- Kawasaki Disease and Coronary Complications
- Neuroinflammation and Neurodegeneration Mechanisms
- Immune cells in cancer
- Glaucoma and retinal disorders
- Pancreatic and Hepatic Oncology Research
- Signaling Pathways in Disease
- Ferroptosis and cancer prognosis
- Cell Adhesion Molecules Research
- Ocular Surface and Contact Lens
- Retinal Imaging and Analysis
- Preterm Birth and Chorioamnionitis
- Vascular Malformations Diagnosis and Treatment
- Corneal Surgery and Treatments
- Epigenetics and DNA Methylation
- Intracranial Aneurysms: Treatment and Complications
- Caveolin-1 and cellular processes
- Ocular Disorders and Treatments
Wenzhou Medical University
2019-2024
Affiliated Eye Hospital of Wenzhou Medical College
2019-2024
Zhengzhou University
2024
Immune checkpoint blockade (ICB) therapy targeting the programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) axis has achieved considerable success in treating a wide range of cancers. However, most patients with pancreatic cancer remain resistant to ICB. Moreover, there is lack optimal biomarkers for prediction response this therapy. Palmitoylation mediated by family 23 S-acyltransferases, termed zinc finger Asp‐His‐His‐Cys-type palmitoyltransferases (ZDHHC), which precisely control...
Gliomas are the most prevalent primary malignant intracranial tumors, characterized by high rates of therapy resistance, recurrence, and mortality. A major factor contributing to poor prognosis gliomas is their ability diffusely infiltrate surrounding even distant brain tissues, rendering complete total resection almost impossible leading frequent recurrences. The extracellular matrix (ECM) plays a key role in tumor microenvironment may significantly influence glioma progression, therapeutic...
Managing recurrent pterygium combined with symblepharon presents significant challenges in ophthalmology. Clinicians aim to reconstruct the ocular surface, alleviate eye movement restrictions, and minimize recurrence risks.
To report the clinical outcomes and evaluate efficacy of a novel bubble ultra-wide field viewing system for vitreoretinal surgery.Prospective, noncomparative, interventional case series.One hundred fifty-one eyes 146 consecutive patients with proliferative diabetic retinopathy (PDR), vitreous haemorrhage originating from retinal vein occlusion (VH-RVO), epiretinal membrane (EM), macular hole (MH) or detachment (RD) who underwent surgery using were included.A standard phacoemulsification was...
Purpose To evaluate optical quality and intraocular scattering using the Optical Quality Analysis System (OQAS) II in branch retinal vein occlusion (BRVO) to investigate influences of changes on quality.Materials methods Sixty-two patients with diagnosis BRVO were enrolled this prospective, case–control study. The control group consisted patients’ fellow eyes. Initial logMAR visual acuity, central macular thickness, parameters including modulation transfer function cutoff frequency (MTF cut...
Abstract Purpose To investigate the long-term surgical outcomes after treatment with pars plana vitrectomy (PPV) combined photocoagulation in different severities of branch retinal vein occlusion (BRVO) vitreous hemorrhage (VH) order to propose a new grading system. Methods We retrospectively reviewed medical records 117 eyes patients who underwent PPV for VH associated BRVO and were followed up at least 12 months. Preoperative best-corrected visual acuity (BCVA), intervention, final BCVA,...
Abstract Background Immune checkpoint blockade (ICB) therapy targeting the programmed death 1 (PD-1)/programmed death-ligand (PD-L1) axis has achieved considerable success in treating a wide range of cancers. However, most patients are still resistant to ICB and lack optimal biomarkers predict response. Thus, uncovering underlying cellular molecular determinants resistance is needed improve efficacy anti-PD-1/L1 therapy. Palmitoylation mediated by family 23 S-acyltransferases,...